ISSN: 1885-5857 Impact factor 2025 4.2
Corrected proofs Journal pre-proofs

Original article
Gray zone NT-proBNP values and long-term outcomes in emergency department patients without prior heart failure

Valores de NT-proBNP en zona gris y episodios a largo plazo en pacientes atendidos en urgencias sin insuficiencia cardiaca previa

Germán CedielaMaría Victoria Rivera-MorenobGilmar PugnetcRamón Armengol-NaranjoaJuan René Delgado-CornejoaJaime Andrés Alba-RodríguezcÓscar M. PeiróadIsabel Serrano-RodríguezadAna CarrasqueradJosé Luis Ferreiroade
https://doi.org/10.1016/j.rec.2026.08.011
La versión en español de este artículo estará disponible en breve
Supplementary data
Imagen extra
10.1016/j.rec.2026.08.011
Abstract
Introduction and objectives

The clinical significance of gray zone N-terminal pro-B-type natriuretic peptide (NT-proBNP) values in the emergency department (ED) remains poorly defined in patients without prior heart failure (HF). We aimed to determine whether, among ED patients without prior HF who did not meet age-adjusted rule-in criteria, gray zone NT-proBNP values were associated with worse long-term outcomes compared with rule-out values.

Methods

This retrospective, observational study included consecutive patients presenting to a tertiary care ED between March and August 2022 who underwent NT-proBNP testing. Patients with prior HF or NT-proBNP values above age-adjusted rule-in thresholds were excluded. First HF hospitalization and all-cause mortality were analyzed as 2 separate, independent outcomes.

Results

A total of 454 patients were included, of whom 228 (50.2%) had gray zone NT-proBNP values and 226 (49.8%) had rule-out values. During a median follow-up of 2.7 years, patients with gray zone values had significantly higher rates of first HF hospitalization (24.1% vs 2.2%) and mortality (36.4% vs 5.3%). After multivariable adjustment, gray zone NT-proBNP values were associated with first HF hospitalization (subdistribution hazard ratio [HR], 6.53; 95%CI, 2.38-17.89; P <.001) and all-cause mortality (HR, 4.59; 95%CI, 2.35-8.94; P <.001).

Conclusions

In ED patients without prior HF, gray zone NT-proBNP values were associated with higher long-term risks of HF hospitalization and all-cause mortality compared with rule-out values. Prospective studies are needed to determine whether structured evaluation of this population improves clinical outcomes.

Keywords

NT-proBNP
Heart failure
Emergency department
Prognosis

Abbreviations

COPD
eGFR
ED
HF
NT-proBNP
sHR

Identify yourself

Not yet a subscriber to the journal?

Purchase access to the article

By purchasing the article, the PDF of the same can be downloaded

Price: 19,34 €

Phone for incidents

Monday to Friday from 9am to 6pm (GMT+1) except for the months of July and August, which will be from 9am to 3pm

Calls from Spain 932 415 960
Calls from outside Spain +34 932 415 960
References
[1]
J.L. Januzzi, R. van Kimmenade, J. Lainchbury, et al.
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study.
Eur Heart J., (2006), 27 pp. 330-337
[2]
C. Mueller, K. McDonald, R.A. de Boer, et al.
Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.
Eur J Heart Fail., (2019), 21 pp. 715-731
[3]
J.L. Januzzi Jr., A.A. Chen-Tournoux, R.H. Christenson, et al.
N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study.
J Am Coll Cardiol., (2018), 71 pp. 1191-1200
[4]
K. Dickstein, A. Cohen-Solal, G. Filippatos, et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).
Eur Heart J., (2008), 29
[5]
P. Ponikowski, A.A. Voors, S.D. Anker, et al.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Eur Heart J., (2016), 37 pp. 2129-2200
[6]
T.A. McDonagh, M. Metra, M. Adamo, et al.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J., (2021), 42 pp. 3599-3726
[7]
R.R. van Kimmenade, Y.M. Pinto, J.L. Januzzi Jr..
Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations.
Am J Cardiol., (2008), 101 pp. 39-42
[8]
S. Anwaruddin, D.M. Lloyd-Jones, A. Baggish, et al.
Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.
J Am Coll Cardiol., (2006), 47 pp. 91-97
[9]
A. Bayes-Genis, K.F. Docherty, M.C. Petrie, et al.
Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC.
Eur J Heart Fail., (2023), 25 pp. 1891-1898
[10]
S.H. Tsai, Y.Y. Lin, S.J. Chu, C.W. Hsu, S.M. Cheng.
Interpretation and use of natriuretic peptides in non-congestive heart failure settings.
Yonsei Med J., (2010), 51 pp. 151-163
[11]
P.A. Heidenreich, B. Bozkurt, D. Aguilar, et al.
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation., (2022), 145 pp. e895-e1032
[12]
A.S. Levey, L.A. Stevens, C.H. Schmid, et al.
A new equation to estimate glomerular filtration rate.
Ann Intern Med., (2009), 150 pp. 604-612
[13]
Siemens Healthcare Diagnostics Inc.
Atellica® IM NT-proBNP (PBNP) Assay [package insert].
Siemens Healthcare Diagnostics Inc., (2022),
[14]
C.K. Brenden, J.E. Hollander, D. Guss, et al.
Gray zone BNP values in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study.
Am Heart J., (2006), 151 pp. 1006-1011
[15]
P.S. Jhund.
Use of NT-proBNP for the screening, diagnosis and risk-stratification of left ventricular dysfunction.
Diabetes Obes Metab., (2025), 27 pp. 7-14
[16]
B. Bozkurt, A.J. Coats, H. Tsutsui, et al.
Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology.
Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail., (2021), 27 pp. 387-413
[17]
K. Souffront, B.P. Nelson, M. Lukas, et al.
B-Type Natriuretic Peptide as a Marker of Subclinical Heart Disease in a High-Burden Emergency Department Population With Sustained Asymptomatic Hypertension.
Int J Hypertens., (2025), 2025 pp. 9951414
[18]
A. Harrison, L.K. Morrison, P. Krishnaswamy, et al.
B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea.
Ann Emerg Med., (2002), 39 pp. 131-138
[19]
S. Hendricks, I. Dykun, B. Balcer, M. Totzeck, T. Rassaf, A. Mahabadi.
Higher BNP/NT-proBNP values stratify prognosis equally well in patients with and without heart failure: a meta-analysis with more than 89,000 patients.
ESC Heart Fail., (2022), 9 pp. 3198-31209
[20]
J.B. Tcheugui, S. Zhang, J.W. McEvoy, et al.
Elevated NT-ProBNP as a Cardiovascular Disease Risk Equivalent: Evidence from the Atherosclerosis Risk in Communities (ARIC) Study.
Am J Med., (2022), 135 pp. 1461-1467
[21]
C.E. Ndumele, K. Matsushita, Y. Sang, et al.
N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study.
Circulation., (2016), 133 pp. 631-638
[22]
D. Aguiar, R. Gonzalez-Manzanares, M. Raya-Cruz, et al.
Improvement initiatives in the diagnostic process of heart failure: a scoping review.
Front Cardiovasc Med., (2026), 12 pp. 1681976
[23]
M. Ledwidge, J. Gallagher, C. Conlon, et al.
Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.
JAMA., (2013), 310 pp. 66-74
Copyright © 2026. Sociedad Española de Cardiología